Segment and Geographic Information

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Segment and Geographic Information

Segment and Geographic Information

The Company manages its business and operations as one segment and is focused on advancing the treatment of acute and intensive care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. Revenues reported to date are derived primarily from the sales of Angiomax in the United States.

The geographic segment information provided below is classified based on the major geographic regions in which the Company operates.

	Three Months Ended March 31,
	2014				2013
	(in thousands)
Net revenue:
United States	$	167,480	94.5	%	$	144,196	92.6	%
Europe	8,719		4.9	%	10,385		6.7	%
Rest of world	1,036		0.6	%	1,172		0.7	%
Total net revenue	$	177,235	100.0	%	$	155,753	100.0	%

	March 31, 2014				December 31, 2013
	(in thousands)
Long-lived assets:
United States	$	1,133,084	99.1	%	$	1,139,210	99.2	%
Europe	9,769		0.8	%	9,035		0.8	%
Rest of world	663		0.1	%	22		—	%
Total long-lived assets	$	1,143,516	100.0	%	$	1,148,267	100.0	%